A vaccine candidate whose key antigen was created using artificial intelligence has completed its first human safety trial, researchers reported June 4, 2026. The Phase I study, conducted at clinical sites in the United Kingdom, showed the experimental vaccine was well tolerated and prompted immune responses against multiple coronaviruses in healthy adults.
The vaccine, known as pEVAC‑PS, was developed by scientists at the University of Cambridge in partnership with DIOSynVax Ltd. The design process used advanced computational analysis of global virus genetic data to identify shared protein features among a group of coronaviruses related to SARS‑CoV‑2. This approach aimed to create a vaccine antigen capable of stimulating recognition of multiple virus strains rather than a single strain.
The trial enrolled 39 healthy volunteers aged 18 to 50. All participants had previously received standard COVID‑19 vaccines. They were assigned to receive two doses of the candidate vaccine four weeks apart and were monitored for safety, tolerability and early immune responses.
Trial investigators reported no serious adverse events linked to the vaccine. Local reactions such as mild pain at the administration site occurred at expected levels for experimental vaccines. Laboratory tests showed participants developed antibody activity against SARS‑CoV‑2, the virus responsible for COVID‑19, and measurable responses against related viruses in the Sarbeco family, which includes SARS and several bat‑origin coronaviruses.
New Approach to Antigen Design
Traditional vaccine development begins with laboratory studies to isolate and test viral proteins before advancing candidates into clinical trials. In this case, the key antigen component was created through computational analysis of thousands of virus sequences from public databases. Researchers identified protein segments conserved across many coronaviruses and combined them into a single engineered antigen.
This engineered antigen was then incorporated into a DNA vaccine construct. The vaccine was delivered using a needle‑free microfluidic jet injection system designed to introduce DNA directly into tissue without traditional needles. This delivery method has been used in other experimental vaccine studies and is selected for its precision and consistency in administering DNA‑based constructs.
Project sponsors included the University Hospital Southampton NHS Foundation Trust, with financial support from government research funding bodies. The Phase I trial was designed to meet regulatory standards for safety evaluation and to provide initial data on immune activity triggered by the vaccine candidate.
What the Data Showed
Safety assessments focused on physical examinations, blood tests and symptom monitoring. Researchers noted typical short‑term responses, such as mild fatigue or low‑grade fever in some participants, but no severe vaccine‑related issues that would halt progression to further study.
Immune response measurements showed that many participants developed antibody binding and neutralizing activity against SARS‑CoV‑2. Responses against other coronaviruses included measurable increases in antibodies that recognized SARS and several bat virus antigens in laboratory assays. These findings reflect early immune activation signals, not proof of real‑world protection against infection.
Phase I studies are not designed to determine whether a vaccine prevents disease. Later stages of research must involve larger and more diverse populations, longer follow‑up and additional measures of immune strength and duration.
Next Steps in the Clinical Pathway
Following review of Phase I data, trial leaders confirmed plans for a Phase II immunogenicity study involving a larger number of volunteers. This next trial will assess the intensity and breadth of immune responses across different dosage levels and participant groups.
Researchers stress that demonstrating effective protection against infection or disease will require substantial work beyond early‑phase trials. Larger randomized studies with comparison groups and long‑term monitoring will be needed before any regulatory submissions for wider use can be considered.
Safety monitoring and evaluation protocols used in this first study align with international clinical research standards. Independent reviewers oversaw trial conduct to ensure participant welfare and robust data collection.
Industry and Scientific Reactions
Within the scientific community, this milestone has drawn attention because it tests a vaccine antigen designed by computational analysis rather than exclusively by laboratory experimentation. Some researchers see this as a way to expand candidate selection by examining vast amounts of genetic information quickly. Others emphasize that any candidate must still undergo thorough laboratory validation and human testing to verify intended biological effects.
Experts note that computer‑derived design can accelerate early stages of candidate identification but does not replace the need for careful empirical study. Biological systems are complex, and immune responses depend on many factors that only become clear through staged clinical trials.
Vaccine developers and public health research organizations worldwide continue to explore ways to streamline early development, particularly for pathogens with pandemic potential. Hybrid approaches that combine data analysis with traditional laboratory work are increasingly common in early research, though each candidate must stand on its own clinical performance.
Voices from the Research Teams
Leaders of the Cambridge trial emphasized that the project integrated computational analysis with established clinical and laboratory methods. Professor Jonathan Heeney, co‑principal investigator, described the antigen design as derived from comparisons of global virus genetic data to find shared protein features. Clinical coordinators noted that the trial’s safety profile supports continued human evaluation.
Investigators highlighted the importance of participant diversity in upcoming trial phases, including a broader range of ages and health backgrounds. They also plan to measure immune responses over extended periods to assess how long vaccine‑induced antibodies persist and how they evolve.
Disclaimer: The vaccine candidate described is in early-stage clinical testing. Further studies are required to determine real-world protection, long-term effects, and broader applicability. This information is provided for educational purposes and does not constitute medical advice. Individuals should consult qualified healthcare professionals regarding vaccination decisions.
